Helfritz FA et al., 2018-10-20: Proof-of-concept study showing methylene blue flushing inactivates HCV in contaminated pig kidneys during cold ischemia and prevents infection in human-liver chimeric mice. Animal and ex-vivo organ work, not treatment of hepatitis C in patients.
Only MB completely inactivated HCV in the presence of all perfusion solutions. Hepatitis C virus-contaminated kidneys from mini pigs were treated with MB and hypothermic machine perfusion without any negative effect on the graft. Human liver-uPA-SCID mice did not establish HCV infection after inoculation with flow through from these kidneys.
Helfritz FA et al., 2018-10-20: Proof-of-concept study showing methylene blue flushing inactivates HCV in contaminated pig kidneys during cold ischemia and prevents infection in human-liver chimeric mice. Animal and ex-vivo organ work, not treatment of hepatitis C in patients. Study type: ex vivo pig-kidney perfusion plus human liver-uPA-SCID mouse infection assay. N not stated in abstract. Country: Germany (University Hospital Essen). MB concentration/route: organ flush during hypothermic machine perfusion, dose not in abstract. Funding/conflicts: none stated in record. Comparator: three antivirals in preservation solutions. Bearing PARTLY because it is graft decontamination, not antiviral therapy. Study type: animal.
